Standard BioTools
LAB
159 hedge funds and large institutions have $387M invested in Standard BioTools in 2025 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 51 reducing their positions, and 14 closing their positions.
57% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 14
3.89% more ownership
Funds ownership: 74.82% → 78.71% (+3.9%)
3% more funds holding
Funds holding: 155 → 159 (+4)
4% more capital invested
Capital invested by funds: $372M → $387M (+$15.9M)
8% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 51
25% less call options, than puts
Call options by funds: $51K | Put options by funds: $68K
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
CC
Casdin Capital
New York
|
+$15.1M |
| 2 |
MCO
MAK Capital One
New York
|
+$4.51M |
| 3 |
Millennium Management
New York
|
+$2.6M |
| 4 |
Morgan Stanley
New York
|
+$1.8M |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.77M |
Top Sellers
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$1.42M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.42M |
| 3 |
PCP
Pacific Capital Partners
London,
|
-$1.14M |
| 4 |
Goldman Sachs
New York
|
-$1.03M |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
-$1M |
LAB Hedge Fund Activity: Q4 2025 in Review
159 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2025, worth a combined $387M — up 4.3% from $372M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LAB positions and 14 closed out — a net gain of 8 holders — while 47 added to existing stakes and 51 trimmed.
The largest buyer was Casdin Capital, adding an estimated $15.1M. The largest seller was Nikko Asset Management Americas, cutting an estimated $1.42M.
- 159 institutional investors held Standard BioTools (LAB) as of Q4 2025, up from 155 in Q3 2025.
- Funds reported $387M of Standard BioTools stock for Q4 2025, up 4.3% quarter-over-quarter.
- 22 funds opened new Standard BioTools positions in Q4 2025 and 14 closed out, a net change of +8 holders.
- The largest Standard BioTools buyer in Q4 2025 was Casdin Capital, an estimated $15.1M added.
- The largest Standard BioTools seller in Q4 2025 was Nikko Asset Management Americas, an estimated $1.42M sold.
Based on aggregated 13F filings for Q4 2025.